atai Life Sciences has announced results from its Phase 1 Study of DMX-1002 (Ibogaine) for the treatment of opioid use disorder (OUD).
A novel compound similar in structure to the psychedelic drug ibogaine, but which has no hallucinogenic effects, has been found to rapidly reverse the effects of...